One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugsIMX-110 is in […]
LOS ANGELES, May 09, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directors has authorized a share repurchase program to acquire up to $1 […]
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities presented by current market volatilityImmixBio plans to commence 2 clinical trials in 2022 LOS ANGELES, April 05, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical […]
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29ada955-df7a-4722-968a-3a3e0fd0d34d LOS ANGELES, March […]
– IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells – ImmixBio anticipates filing an IND for IMX-120 in 2023 – The inflammatory bowel disease market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in […]
LOS ANGELES, Feb. 01, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day […]
January 31, 2022 08:00 ET | Source: Immix Biopharma, Inc. – Manufactured IMX-110 to be utilized in both clinical trials: – 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) – 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid […]
– IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system – Historically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and […]
– 100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial – IMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 billion market expected to grow to $6.5 billion by […]
– IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer – soft tissue sarcoma (STS) mice study – IMX-110 response rate surpassed standard of care doxorubicin’s response rate of 0% after 1 cycle of treatment in the same […]
Los Angeles, CA, Jan. 06, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the IMMX Investors Day Event, to be held on February 1, 2022, and the launch […]
January 03, 2022 08:00 ET | Source: Immix Biopharma, Inc. – Rare Pediatric Disease Designation (“RPDD”) qualifies Immix Biopharma to receive fast track review, and a priority review voucher (“PRV”) at the time of marketing approval of IMX-110. – PRV holders can benefit from an expedited […]
LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common […]
LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today the pricing of its initial public offering of 4,200,000 shares of its common stock […]
Sep 30, 2021, 08:38 ET LOS ANGELES, Sept. 30, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and inflammation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to IMX-110 […]
Novel Approach Combining ImmixBio Tissue Specific Therapeutics (TSTx)™ with Immunotherapies Could Expand the Population Of Cancer Patients Experiencing Extended Remissions News provided byImmix Biopharma, Inc.Aug 27, 2021, 08:31 ET LOS ANGELES, Aug. 27, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”) today announced a clinical trial and […]
Dr. Galit Lahav, pioneer of understanding why individual human cancer cells often show different responses to the same treatment (including p53 and NF-kB signaling dynamics), and identifying new therapies that will increase the efficacy of anti-cancer drugs News provided byImmix Biopharma, Inc.Aug 17, 2021, 08:44 ET […]
Dr. George W. Sledge, former ASCO president, pioneering clinical investigator of multiple approved cancer therapeutics including multi-kinase inhibitor abemaciclib (marketed as VERZENIO® by Eli Lilly) and paclitaxel News provided byImmix Biopharma, Inc.Aug 09, 2021, 08:38 ET LOS ANGELES, Aug. 9, 2021 /PRNewswire/ — Immix Biopharma, Inc. […]